



PTO/SB/08A/B (07-05)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/612,832		
		Filing Date	July 1, 2003		
		First Named Inventor	Stein, Harald		
		Art Unit	1642		
		Examiner Name	Lei Yao		
Sheet	1	of	1	Attorney Docket Number	086035-000000US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
LY	AB	WO	94/04189		03/03/1994	STEIN, et al.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LY	BA	TERENZI, et al. "Anti-CD30 (BER-H2) immunotoxins containing the type1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30 ⁺ tumour cells <i>in vitro</i> and in SCID mice"; <i>British Journal of Haematology</i> (1996) 92: 872-879.	<input type="checkbox"/>
LY	BB	CHEONG, et al. "Affinity enhancement of bispecific antibody against two different epitopes in the same antigen"; <i>Biochemical and Biophysical Research Communications</i> ; Vol. 173, No. 3, (1990), 795-800.	<input type="checkbox"/>
LY	BC	LU, et al. "Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2"; <i>Journal of Immunological Methods</i> ; 230 (1999) 159-171.	<input type="checkbox"/>
LY	BD	KLIMKA, et al. "Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning"; <i>British Journal of Cancer</i> (2000) 83(2), 252-260.	<input type="checkbox"/>
LY	BE	DONG, et al. "Human CD30: Structural implications from epitope mapping and modeling studies"; <i>J. Mol. Recognit</i> (2003); 16: 28-36.	<input type="checkbox"/>
LY	BF	DÜRKOP, et al. "Structure of the Hodgkin's lymphoma-associated human CD30 gene and the influence of a microsatellite region on its expression in CD30 ⁺ cell lines"; <i>Biophysica Acta</i> ; 1519 (2001); 185-191.	<input type="checkbox"/>
LY	BG	HANSEN, et al. "Ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5"; <i>The FASEB Journal</i> ; Express Article 10.1096/fg.03-0901 fje. Published online March 19, 2004.	<input type="checkbox"/>

Examiner Signature	/Lei Yao/	Date Considered	10/31/2006
--------------------	-----------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.